Thermo Fisher will acquire Clario, a clinical trial software leader, for up to $9.4B, expanding its digital and AI-driven clinical research capabilities.

Novo Nordisk's $6.5 billion bid for Metsera tops Pfizer, escalating the race for next-generation obesity treatments and sparking legal and regulatory challenges.

Takeda seals a $1.2 billion upfront deal with Innovent Biologics for late-stage cancer therapies, positioning to expand its oncology pipeline and offset patent losses.

Galapagos will close its cell therapy unit after failing to secure a buyer, impacting 365 employees and multiple global sites. The Belgian biotech shifts focus to acquisitions and building its medicine pipeline.

BioCryst Pharmaceuticals is acquiring Astria Therapeutics in a $700 million cash-and-stock deal, aiming to challenge major players in the hereditary angioedema (HAE) drug market with a broader, dual-therapy portfolio.

AI investment in 2025 is shifting from hype and promise to tangible proof and measurable returns. Investors now require case studies and real-world data before committing funds, marking a new phase for startups and industry growth.

Novo Nordisk has struck a $2.1B licensing deal with Omeros for global rights to zaltenibart, a first-in-class MASP-3 inhibitor for rare diseases.

DUOS, a senior-focused health tech company, has raised $130 million to advance its AI-powered platform and grow payer partnerships, signaling rising demand for digital senior care solutions.